Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Medley

Urology New Albany, IN Medical Doctor

NPI 1578550638 CMS profile 465041

1919 State St, New Albany, IN 47150

Open in the dashboard

General payments

$35,432

599 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$4,885

2 holdings reported · through program year 2025

Through program year 2025, Richard Medley of New Albany, IN is reported in the CMS Open Payments database as having received $35,432 across 599 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $4,885 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,144 92
2024 General $8,785 86
2023 General $4,719 98
2022 General $5,149 103
2021 General $4,377 97
2020 General $1,445 56
2019 General $3,812 67
2025 Ownership $2,369 1
2024 Ownership $2,517 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Medley
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Richard Medley were reported at $7,144. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Richard Medley Urology median Middle half National median
2019 $3,812 $480 $147–$1,201 $163
2020 $1,445 $246 $87–$645 $114
2021 $4,377 $358 $111–$1,000 $132
2022 $5,149 $476 $143–$1,263 $149
2023 $4,719 $560 $168–$1,461 $160
2024 $8,785 $563 $170–$1,464 $164
2025 $7,144 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teleflex LLC $6,536 47 payments
  2. Urogen Pharma, Inc. $4,189 31 payments
  3. Medtronic, Inc. $3,772 67 payments
  4. Boston Scientific Corporation $2,760 35 payments
  5. Janssen Biotech, Inc. $2,024 38 payments
  6. Telix Pharmaceuticals $1,943 9 payments
  7. Calyxo, Inc. $1,565 13 payments
  8. Axonics Modulation Technologies, Inc. $1,495 15 payments
  9. Sumitomo Pharma America, Inc. $1,125 37 payments
  10. Astellas Pharma US Inc $932 39 payments
  11. Other $9,090 268 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,318 562 payments
  2. Travel and Lodging $8,763 32 payments
  3. Honoraria $3,125 1 payment
  4. Consulting Fee $1,000 1 payment
  5. Education $188 2 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38 1 payment
Products named General payments · program years 2019–2025
  1. UROLIFT Interventional Urology $4,211 33 payments
  2. JELMYTO $4,124 29 payments
  3. INTERSTIM $3,446 62 payments
  4. ERLEADA $1,803 36 payments
  5. UROLIFT Interventional Urology $1,576 3 payments
  6. CVAC ASPIRATION SYSTEM $1,491 9 payments
  7. Bulkamid $1,380 13 payments
  8. Axonics r-SNM System $1,314 12 payments
  9. BARRIGEL $1,174 2 payments
  10. XIAFLEX $1,089 50 payments
  11. Other $18,384 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

2,103

Median for Urology: 1,053

Drug cost

$488,770

Median for Urology: $101,464

Branded share of claims

57.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 322 $296,505
Gemtesa Vibegron Brand 183 $153,580
Mirabegron Er Mirabegron Brand 14 $8,085
Xyosted Testosterone Enanthate Brand 11 $6,819
Tamsulosin Hcl Generic 430 $5,358
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 51 $4,530
Tolterodine Tartrate Er Tolterodine Tartrate Brand 18 $3,447
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 227 $1,803
Alfuzosin Hcl Er Alfuzosin Hcl Brand 71 $1,559
Finasteride Generic 80 $992

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$578,797

Of which drugs: $168,620

Medicare patients

1,376

Average age 74

Services billed

8,968

383 women, 993 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 35%
Cancer 35%
Chronic kidney disease 29%
Atrial fibrillation 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $3,515
$3,515 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $244
$244 — —
XIAFLEX
  • Endo USA, Inc. $120
  • Endo Pharmaceuticals Inc. $48
$168 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $143
$143 183 —
Trelstar
  • Verity Pharmaceuticals Inc. $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

599 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record